

SMS PHARMACEUTICALS LIMITED

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Statement of Standalone Un-Audited Financial Results for the Quarter and Half Year Ended 30th September, 2018

(Rs. In Lakhs)


S.No	Particulars	Quarter Ended			Half Year ended		Year ended
		30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	13,484.05	12,510.66	12,728.67	25,994.71	25,990.47	46,486.33
2	Other Income	148.60	36.14	112.41	184.74	154.25	238.79
3	Total Revenue	13,632.65	12,546.80	12,841.08	26,179.46	26,144.72	46,725.12
4	Expenses						
	(a) Cost of Materials Consumed	9,971.38	8,339.98	9,854.31	18,311.36	17,531.17	29,432.23
	(b) Changes in Inventories	(1,269.48)	(302.38)	(1,219.24)	(1,571.86)	319.78	(442.31)
	(c) Central Excise Duty	-	-	-	-	261.58	218.81
	(d) Manufacturing Expenses	992.25	1,032.25	937.05	2,024.50	1,737.93	3,450.40
	(e) Employee Benefits Expense	902.97	859.82	775.37	1,762.79	1,490.58	3,280.34
	(f) Finance Cost	295.14	301.87	426.76	597.01	777.82	1,547.96
	(g) Depreciation and Amortization Expense	481.92	475.34	496.73	957.26	990.28	1,989.98
	(f) Other Expenses	354.21	210.44	316.12	564.65	553.42	1,212.89
	Total Expenses - (a to f)	11,728.39	10,917.32	11,587.10	22,645.71	23,662.56	40,690.30
5	Profit before Exceptional and Extraordinary Items and Tax (3-4)	1,904.26	1,629.48	1,253.98	3,533.74	2,482.16	6,034.82
6	Exceptional items	-	-	-	-	-	-
7	Profit before Extraordinary Items and Tax (5-6)	1,904.26	1,629.48	1,253.98	3,533.74	2,482.16	6,034.82
8	Extraordinary Items	-	-	-	-	-	-
9	Profit before Tax (7-8)	1,904.26	1,629.48	1,253.98	3,533.74	2,482.16	6,034.82
10	Tax Expenses						
	(1) Current Tax (MAT)	450.00	350.00	276.64	800.00	541.64	1,276.15
	(2) Deferred Tax	198.45	268.05	40.18	466.50	80.26	713.24
11	Net Profit / (Loss) for the Period (9-10)	1,255.81	1,011.43	937.16	2,267.24	1,860.26	4,045.43
12	Other Comprehensive Income (OCI):						
	Items that will not be reclassified to profit or Loss:	(2.37)	(1.58)	(6.54)	(3.94)	(16.61)	6.31
	Tax on Items that will not be reclassified to profit or Loss:	(0.83)	(0.55)	-	(1.38)	-	2.20
		(1.54)	(1.03)	(6.54)	(2.57)	(16.61)	4.11
13	Total comprehensive Income for the period (11+12)	1,254.27	1,010.40	930.62	2,264.68	1,843.65	4,049.54
14	Earning Per Equity Share	1.48	1.19	1.11	2.68	2.20	4.78
	(of Re.1/ each) (not annualised)						
	(a) Basic						
	(b) Diluted						
	Paid-up equity share capital (Face Value of Re.1/- each)	846.52	846.52	846.52	846.52	846.52	846.52
	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						



Statement of Assets & Liabilities as at 30th September, 2018

(Rs.in Lakhs)

Sr.No	Particulars	As at	As at
		30.09.2018 (Unaudited)	31.03.2018 (Audited)
A	ASSETS		
1	Non-Current Assets		
	(a) Property, Plant and Equipment	27,041.28	27,889.89
	(b) Capital Work-in-Progress	1,331.62	819.66
	(c) Intangible Assets	32.44	36.27
	(d) Financial Assets:		
	(i) Investments	4,499.87	4,499.87
	(ii) Bank Balances	206.92	200.78
	(iii) Other Financial Assets	366.89	238.68
	(e) Other Non-Current Assets	2,165.71	1,380.46
	Sub Total :Non-Current Assets	35,644.73	35,065.61
2	Current Assets		
	(a) Inventories	10,997.91	10,747.53
	(b) Financial Assets		
	(i) Trade Receivables	2,192.74	2,414.92
	(ii) Cash and Cash Equivalents	24.85	1,263.08
	(iii) Bank Balances (Other than (ii) above)	10.13	8.01
	(iv) Other Financial Assets	10.27	53.52
	(c) Other Current Assets	3,157.52	2,361.64
	(d) Current Tax Asset (Net)		
	Sub Total : Current Assets	16,393.42	16,848.70
	TOTAL ASSETS	52,038.15	51,914.31
B	EQUITY AND LIABILITIES		
1	Equity:		
	(a) Equity Share Capital	846.52	846.52
	(b) Other Equity	31,273.59	29,264.04
	Sub-Total -Shareholders' funds	32,120.11	30,110.56
	Liabilities:		
2	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	6,542.93	7,139.82
	(b) Provisions	255.38	217.87
	(c) Deferred Tax Liabilities (net)	2,765.43	2,300.32
	Sub-Total -Non-Current Liabilities	9,563.74	9,658.01
3	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	3,172.67	5,839.71
	(ii) Trade Payables:	4,614.32	3,870.37
	(iii) Other Financial Liabilities	1,560.11	1,754.76
	(b) Provisions	71.50	71.50
	(c) Other Current Liabilities	810.01	592.90
	(d) Current Tax Liabilities (Net)	125.69	16.50
	Sub-Total - Current Liabilities	10,354.30	12,145.74
	TOTAL - EQUITY AND LIABILITIES	52,038.15	51,914.31



Notes:

- 1 The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 10th November, 2018 and have been approved by the Board of Directors at its meeting held on 10th November, 2018.
- 2 Results for the quarter ended 30th September, 2018 were subjected to 'Limited Review' by the Auditors.
- 3 The above results are in accordance with the companies (Indian Accounting Standards) rules, 2015, (Ind AS) as amended by Company (Ind AS) (amendment) Rules, 2016, notified under Section 133 of the Companies Act 2013, read with relevant Rules issued there under and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- 4 The Company is engaged in the manufacturing Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 5 As per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
- 6 Post implementation of Goods and Service Tax (GST) effective from 1st July, 2017, revenue is reported net of GST as per Ind AS-18. Revenue, however, is reported inclusive of excise duty for a part of the period ended 30th September, 2017. Had the previously reported revenue been shown net of excise duty, comparative revenue of the company would have been as under:

Particulars	Quarter ended			Half Year ended		Year ended
	30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
Revenue from operations (net of excise duty)	13,484.05	12,510.66	12,728.67	25,994.71	25,735.30	46,231.16

- 7 As approved by the Members of the company at the 30th Annual General Meeting held on 20th September, 2018, the company has disbursed on 24th September, 2018 a dividend of Rs.0.25 per equity share of Re.1 each for the year ended 31st March, 2018, aggregating to Rs.211.66 lakhs and also remitted an amount of Rs 43.50 Lakhs towards Dividend Distribution Tax

Place: Hyderabad
Date : 10-11-2018



For SMS Pharmaceuticals Limited

A handwritten signature in blue ink, appearing to read "Ramesh Babu Potluri".

Ramesh Babu Potluri
Chairman and Managing Director



Limited Review Report

To
The Board of Directors
SMS PHARMACEUTICALS LIMITED
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of SMS PHARMACEUTICALS LIMITED ("the Company"), for the quarter ended 30th September 2018 ("the statement"), being submitted by the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July,2016.


This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July,2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 10-11-2018

For Suryanarayana & Suresh.,
Chartered Accountants
Reg. No.006631S


V Nagendra Rao

Partner
M. No. 227679

